Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model.
For many nonmalignant hematological disorders, HLA-matched bone marrow transplantation (BMT) is curative. However, due to lack of neoplasia, the toxicity of stringent conditioning regimens is difficult to justify, and reduced intensity conditioning is used. Unfortunately, current reduced intensity regimens have high rates of BMT rejection. We have recently reported in a murine model that mHAs on transfused platelet products induce subsequent BMT rejection. Most nonmalignant hematological disorders require transfusion support prior to BMT and the rate of BMT rejection in humans correlates with the number of transfusions given. Herein, we perform a mechanistic analysis of platelet transfusion-induced BMT rejection and report that unlike exposure to alloantigens during transplantation, platelet transfusion primes alloimmunity but does not stimulate full effector function. Subsequent BMT is itself an additional and distinct immunizing event, which does not induce rejection without antecedent priming from transfusion. Both CD4(+)  and CD8(+)  T cells are required for priming during platelet transfusion, but only CD8(+)  T cells are required for BMT rejection. In neither case are antibodies required for rejection to occur.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
S R
SR
Patel
N H
NH
Smith
L
L
Kapp
J C
JC
Zimring
D000818:Animals; D001792:Blood Platelets / Q000276:immunology; D001855:Bone Marrow Diseases / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D019084:Fluorescent Antibody Technique, Indirect; D006084:Graft Rejection / Q000209:etiology*; D006801:Humans; D008285:Major Histocompatibility Complex / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D017713:Platelet Transfusion / Q000009:adverse effects*; D014184:Transplantation, Homologous